SOTIO will present three posters, including a late breaking poster on the clinical data from the ongoing Phase 1 study of IL-15 superagonist SO-C101 for the treatment of advanced solid tumors

PRAGUE, Czech Republic, November 04, 2020 / B3C newswire / -- SOTIO, a clinical stage immuno-oncology company, and Cytune Pharma, both owned by PPF Group, today announced that they will present a late breaking poster highlighting new clinical data on SO-C101 at the Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting to be held virtually November 9-14, 2020. SO-C101 is an IL-15 superagonist currently being investigated in a Phase 1 trial for the treatment of advanced solid tumors. Two additional posters will also be presented summarizing the latest preclinical data on SO-C101.

Late breaking poster details:

Title: A multicenter open-label phase 1/1b study of SO-C101 as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors  Poster Number: 807 Session: In-Progress Clinical Trials Presenting Author: Aurélien Marabelle, M.D., Ph.D. Date/ Time: Wednesday, November 11, from 5:15-5:45 p.m. EST and Friday, November 13 from 4:40-5:10 p.m. EST

Poster presentation details:

Title: Pharmacodynamics and pharmacokinetics of SO-C101 in cynomolgus monkeys  Poster Number: 563 Session: Immune-stimulants and immune modulators Presenting Author: Irena Adkins, Ph.D. Date/ Time: Wednesday, November 11, from 5:15-5:45 p.m. EST and Friday, November 13 from 4:40-5:10 p.m. EST

Title: SO-C101 induces NK cell cytotoxicity and potentiates antibody-dependent cell cytotoxicity and anti-tumor activity Poster Number: 562 Session: Immune-stimulants and immune modulators Presenting Author: Irena Adkins, Ph.D. Date/ Time: Thursday, November 12, from 4:50-5:20 p.m. EST and Saturday, November 14 from 1:00-1:30 p.m. EST

Selected presentation materials will be made available on the SOTIO website once the presentations conclude.

Cytune Pharma is responsible for the clinical development of SO-C101 and SOTIO is a sponsor of the Phase 1 clinical trial.

About SOTIO SOTIO is shaping the future of cancer immunotherapies by translating compelling science into patient benefit. SOTIO’s robust clinical pipeline includes a differentiated superagonist of the attractive immuno-oncology target IL-15, a platform to streamline personalized active immune cell therapies and a new generation of potent and stable antibody-drug conjugates (ADCs). SOTIO is a member of the PPF Group.

SOTIO is a registered trademark of SOTIO a.s. in selected countries.

Contacts

Company contact Richard Kapsa Head of Communication T: (+420) 224 174 448 M: (+420) 603 280 971 kapsa@sotio.com

Media contact Kirsten Frazer, Ph.D. LifeSci Communications +1 646-863-0222 kfrazer@lifescicomms.com

Keywords: Humans; Clinical Trials, Phase I as Topic; Medical Oncology; IL15 protein, human; Interleukin-15; Receptors, Interleukin-15; Melanoma; Neoplasms; Immunotherapy; pembrolizumab; Immunoconjugates; Antibody-Dependent Cell Cytotoxicity; Antibodies, Monoclonal; Humanized; Immunologic Factors; Killer Cells, Natural; Longitudinal Studies

Published by B3C newswire

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.